サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758052

気管支拡張症治療薬の世界市場

Bronchiectasis Drugs

出版日
ページ情報
英文 207 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.41円
気管支拡張症治療薬の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 207 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

気管支拡張症治療薬の世界市場は2030年までに11億米ドルに達する見込み

2024年に6億2,710万米ドルと推定される気管支拡張症治療薬の世界市場は、2024年から2030年にかけてCAGR 10.5％で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗生物質は、CAGR 10.0％を記録し、分析期間終了時には6億6,870万米ドルに達すると予測されます。去痰薬セグメントの成長率は分析期間中CAGR 11.8%と推定されます。

米国市場は1億7,090万米ドルと推定、中国はCAGR 14.1％で成長予測

米国の気管支拡張症治療薬市場は、2024年に1億7,090万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを14.1%として、2030年までに2億3,300万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.6%と9.2%と予測されています。欧州では、ドイツがCAGR約8.2%で成長すると予測されています。

世界の気管支拡張症治療薬市場- 主要動向と促進要因まとめ

なぜ気管支拡張症が呼吸器医療における重要な焦点として再浮上しているのか？

気管支拡張症は、かつては希少疾患と考えられていましたが、世界の有病率の上昇と慢性的で衰弱しやすい疾患であるという認識の高まりにより、呼吸器内科で再び注目を集めています。不可逆的な気管支拡張、慢性感染、過剰な粘液産生を特徴とする気管支拡張症は、肺機能と生活の質を著しく損なう。以前は、嚢胞性線維症に続発するまれな疾患と考えられていたが、現在では、特に高齢者や呼吸器感染症を繰り返す人の間で、単独の非嚢胞性線維症（NCFBE）として診断されることが多くなっています。診断能力の向上、特に高解像度CTスキャンの普及が、世界の発見率の向上に寄与しています。この疾患は、免疫不全や感染後の損傷から自己免疫疾患や慢性的な誤嚥に至るまで、複雑かつ不均一な病因を持つため、個別化された治療戦略が必要となります。気管支拡張症の負担が増加しているにもかかわらず、現在、気管支拡張症に特化したFDA承認の薬剤はなく、疾患の管理は、抗生物質、抗炎症剤、気管支拡張剤、粘液溶解剤などの適応外使用に頼り、対症療法的なものとなっています。このような治療上のギャップは、呼吸器治療薬市場において大きなアンメットニーズを引き起こし、標的療法に焦点を当てた研究開発のきっかけとなっています。臨床医や患者の間で認知度が高まるにつれ、気管支拡張症は顧みられない疾患から薬剤介入の戦略的ターゲットへと移行しつつあり、感染の制御、炎症の軽減、疾患の進行阻止を目的とした新しい薬剤クラス別や新規デリバリーシステムの開発が促されています。

どのような治療アプローチが気管支拡張症治療薬のパイプラインを形成しているか？

気管支拡張症の現在の治療戦略は、主に感染症の制御、炎症の管理、粘液クリアランスの促進、増悪頻度の減少に焦点を当てています。トブラマイシンやアズトレオナムなどの吸入抗生物質の長期使用は、特に慢性緑膿菌コロニーを有する患者において、最も広く使用されている選択肢の1つです。これらの吸入抗生物質は細菌量を抑制し、肺の損傷を最小限に抑えるのに役立ちます。しかし、これらの適応外使用は、気管支拡張症に特別に承認された薬剤の緊急の必要性を強調しています。アジスロマイシンやクラリスロマイシンのような経口マクロライドもまた、抗生物質としての役割と免疫調節薬としての役割の両方を果たし、抗炎症作用によって増悪率を低下させる。ネブライザーによる高張食塩水やマンニトールは一般的に処方される粘液溶解薬で、気道のクリアランスを改善するが、根本的な感染や炎症には直接作用しないです。最近の薬剤開発の動向では、新規の抗炎症剤、好中球エラスターゼ阻害剤、CXCR2拮抗剤などが研究されており、疾患の進行を促す感染と炎症のサイクルを破壊することを目的としています。バイオ製薬会社はまた、重症例や治療抵抗性症例において免疫反応を調節するIL-17やIL-8経路阻害剤などの生物学的製剤の可能性を研究しています。さらに、薬物とデバイスの併用療法や先進的な吸入技術により、下気道へのドラッグデリバリー効率が向上しています。これは、気管支拡張障害の局所的な性質を考慮すると極めて重要です。現在、気管支拡張症患者向けに特別にデザインされた新規分子の安全性と有効性を評価するため、いくつかの臨床試験が第II相および第III相段階にあります。これらのパイプラインの革新は、気管支拡張症が対症療法的な疾患から薬理学的に対処可能な疾患へと変化しつつあることを強調するものであり、この慢性呼吸器疾患に罹患している数百万人に希望をもたらすものです。

人口統計学的および疫学的変化は、気管支拡張症治療薬の市場需要をどのように牽引しているのでしょうか？

気管支拡張症治療薬の需要は、人口の高齢化、慢性呼吸器疾患の増加、診断能力の向上など、人口統計学的・疫学的動向によって大きく形成されています。気管支拡張症は高齢者に最も多く、2050年までに世界の60歳以上の人口は倍増すると予測されており、気管支拡張症の負担もそれに応じて増加すると予想されています。高所得国では、画像診断の進歩により、これまで診断されていなかった症例が発見されるようになり、特に慢性閉塞性肺疾患（COPD）、喘息、関節リウマチなどの疾患を併発している患者において、予想以上の有病率が明らかになっています。中低所得国では、麻疹、結核、肺炎のような小児期の感染症が未治療または不十分な管理のために、感染後気管支拡張症がよくみられます。また、都市化、大気汚染、喫煙も、先進国、発展途上国を問わず大きな要因となっています。さらに、臨床医の意識の向上と報告システムの改善により、この病気が公衆衛生に与える影響が体系的に過小評価されていることが明らかになりました。その結果、より多くの患者が、長期的な管理が必要な慢性呼吸器症状を抱え、ヘルスケアシステムに入ってきています。製薬会社は、気管支拡張症の慢性的な性質と増悪に伴う入院率の高さを考慮し、気管支拡張症が商業的に実行可能な治療ターゲットであることを認識しつつあります。経済的・社会的負担の増大（ヘルスケアコスト、労働時間の損失、QOLの低下など）は、政府や医療制度に気管支拡張症治療への投資を優先させ、医薬品開発とアクセス拡大への関心をさらに高めています。

気管支拡張症治療薬の世界市場成長を促進する力とは？

気管支拡張症治療薬市場の成長は、治療パラダイムの変化、ヘルスケアの優先順位の進化、呼吸器疾患への研究開発投資の増加に直結するいくつかの要因によってもたらされます。とりわけ、承認された疾患特異的治療薬がないため、製薬企業がそのギャップを埋めようとしのぎを削り、臨床試験活動やイノベーション・パイプラインが活発化しています。気管支拡張症は慢性かつ進行性であるため、長期的な薬物療法のターゲットとして有利であり、患者は症状のコントロールと増悪の予防のために継続的な管理を必要とします。さらに、遺伝子やバイオマーカーに基づくプロファイリングが利用可能になりつつあることで、患者の層別化が促進され、精密医療へのアプローチやオーダーメイド治療薬の開発が支援されています。振動メッシュ式ネブライザーやドライパウダー吸入器などの吸入技術の進歩により、肺の患部へのドラッグデリバリーが改善され、全身的な副作用を軽減しながら有効性が高まっています。さらに、規制当局は、希少疾患や顧みられない疾患に対する薬剤開発を奨励するため、より積極的になっており、適格な気管支拡張症治療薬に対して、ファスト・トラック指定、希少疾病用医薬品優遇措置、市場独占権を提供しています。商業的な面では、製薬会社は研究機関やバイオテクノロジー企業との戦略的パートナーシップを活用し、開発期間の短縮とリスクの分担を図っています。新興市場もまた、ヘルスケアのインフラが整備され、呼吸器疾患に対する認識が広まるにつれて、市場浸透の新たな機会をもたらしています。テレヘルス、在宅ネブライザー、デジタルヘルスの統合により、疾病管理はさらに強化され、患者は治療へのアクセスが向上し、アドヒアランスが向上しています。臨床ニーズ、技術力、世界の保健政策に根ざしたこれらの複合的な力が、気管支拡張症治療薬市場を、ターゲットを絞った患者中心の呼吸器ケアの新時代へと牽引しています。

セグメント

製品（抗生物質、去痰薬、その他製品）、流通チャネル（オンライン流通チャネル、オフライン流通チャネル）

調査対象企業の例（全41件）

  • AbbVie Inc.
  • Akorn Operating Co. LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline plc（GSK）
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Insmed Incorporated
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36428

Global Bronchiectasis Drugs Market to Reach US$1.1 Billion by 2030

The global market for Bronchiectasis Drugs estimated at US$627.1 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$668.7 Million by the end of the analysis period. Growth in the Expectorants segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.9 Million While China is Forecast to Grow at 14.1% CAGR

The Bronchiectasis Drugs market in the U.S. is estimated at US$170.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.0 Million by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Bronchiectasis Drugs Market - Key Trends & Drivers Summarized

Why Is Bronchiectasis Re-Emerging as a Critical Focus in Respiratory Medicine?

Bronchiectasis, once considered an orphan condition, is now gaining renewed attention in respiratory medicine due to a rising global prevalence and increased recognition of its chronic and debilitating nature. Characterized by irreversible bronchial dilation, chronic infection, and excessive mucus production, bronchiectasis significantly impairs lung function and quality of life. Previously thought to be rare and mainly secondary to cystic fibrosis, the condition is now increasingly diagnosed as a standalone non-cystic fibrosis (NCFBE) entity, particularly among older adults and individuals with recurrent respiratory infections. Improved diagnostic capabilities, especially the widespread use of high-resolution CT scans, have contributed to higher detection rates worldwide. The condition’s complex and heterogeneous etiology-ranging from immunodeficiencies and post-infectious damage to autoimmune diseases and chronic aspiration-demands personalized treatment strategies. Despite its rising burden, there is currently no FDA-approved drug specifically indicated for bronchiectasis, making disease management largely symptomatic and reliant on off-label use of antibiotics, anti-inflammatories, bronchodilators, and mucolytics. This therapeutic gap has triggered a significant unmet need in the respiratory drug market and has become a catalyst for research and development efforts focused on targeted therapies. As awareness increases among clinicians and patients, bronchiectasis is transitioning from a neglected disorder to a strategic target for pharmaceutical intervention, prompting the development of new drug classes and novel delivery systems aimed at controlling infection, reducing inflammation, and halting disease progression.

What Therapeutic Approaches Are Gaining Ground in the Bronchiectasis Drug Pipeline?

Current treatment strategies for bronchiectasis primarily focus on controlling infections, managing inflammation, facilitating mucus clearance, and reducing exacerbation frequency. Long-term use of inhaled antibiotics, such as tobramycin and aztreonam, is one of the most widely used options, particularly in patients with chronic Pseudomonas aeruginosa colonization. These inhaled antibiotics help suppress bacterial loads and minimize lung damage over time. However, their off-label use highlights the urgent need for drugs specifically approved for bronchiectasis. Oral macrolides like azithromycin and clarithromycin also serve dual roles as both antibiotics and immunomodulatory agents, reducing exacerbation rates through their anti-inflammatory effects. Nebulized hypertonic saline and mannitol are commonly prescribed mucolytics that improve airway clearance but do not directly address the underlying infection or inflammation. Recent advancements in drug development are exploring novel anti-inflammatory agents, neutrophil elastase inhibitors, and CXCR2 antagonists aimed at disrupting the cycle of infection and inflammation that drives disease progression. Biopharmaceutical companies are also investigating the potential of biologics, such as IL-17 or IL-8 pathway inhibitors, to modulate the immune response in severe or treatment-refractory cases. Additionally, drug-device combination therapies and advanced inhalation technologies are improving drug delivery efficiency to the lower airways, which is crucial given the localized nature of bronchiectatic damage. Several clinical trials are currently in phase II and III stages, assessing the safety and efficacy of novel molecules designed specifically for bronchiectasis patients. These pipeline innovations underscore the ongoing transformation of bronchiectasis from a symptom-managed illness to a pharmacologically addressable disease, bringing hope to millions affected by this chronic respiratory disorder.

How Are Demographic and Epidemiological Shifts Driving Market Demand for Bronchiectasis Drugs?

The demand for bronchiectasis drugs is being significantly shaped by demographic and epidemiological trends, including aging populations, rising chronic respiratory illnesses, and improved diagnostic capabilities. The condition is most prevalent among older adults, and with the global population of individuals over 60 projected to double by 2050, the burden of bronchiectasis is expected to increase correspondingly. In high-income countries, advancements in diagnostic imaging have led to greater identification of previously undiagnosed cases, revealing a higher-than-anticipated prevalence, especially in patients with coexisting conditions like chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis. In lower- and middle-income countries, post-infectious bronchiectasis remains common due to untreated or poorly managed childhood infections like measles, tuberculosis, or pneumonia. Urbanization, air pollution, and smoking are also major contributing factors across both developed and developing regions. Furthermore, increased clinician awareness and improved reporting systems have shed light on the systemic underestimation of this disease's impact on public health. As a result, more patients are entering the healthcare system with chronic respiratory symptoms demanding long-term management. Pharmaceutical companies are now recognizing bronchiectasis as a commercially viable therapeutic target, particularly given the chronic nature of the disease and the high rate of hospitalizations associated with exacerbations. The growing economic and societal burden-measured in terms of healthcare costs, workdays lost, and diminished quality of life-is further prompting governments and health systems to prioritize investment in bronchiectasis care, driving interest in drug development and access expansion.

What Forces Are Propelling Global Market Growth for Bronchiectasis Therapeutics?

The growth in the bronchiectasis drugs market is driven by several factors directly linked to shifting therapeutic paradigms, evolving healthcare priorities, and increased R&D investment in respiratory diseases. Foremost, the lack of approved, disease-specific treatments has created a high-value gap that pharmaceutical companies are racing to fill, leading to an uptick in clinical trial activity and innovation pipelines. The chronic and progressive nature of bronchiectasis makes it a lucrative target for long-term pharmacotherapy, with patients requiring continuous management to control symptoms and prevent exacerbations. Additionally, the growing availability of genetic and biomarker-based profiling is enhancing patient stratification, which supports precision medicine approaches and the development of tailored therapeutics. Advances in inhalation technologies-such as vibrating mesh nebulizers and dry powder inhalers-are improving drug delivery to affected lung regions, increasing efficacy while reducing systemic side effects. Moreover, regulatory agencies are becoming more proactive in encouraging drug development for rare and neglected conditions, offering fast-track designations, orphan drug incentives, and market exclusivity to qualifying bronchiectasis therapies. On the commercial front, pharmaceutical companies are leveraging strategic partnerships with research institutions and biotech firms to accelerate development timelines and share risk. Emerging markets are also presenting new opportunities for market penetration, as healthcare infrastructure improves and respiratory disease awareness spreads. Telehealth, home-based nebulization systems, and digital health integration are further enhancing disease management, allowing patients better access to treatments and increasing adherence. These combined forces-rooted in clinical need, technological capability, and global health policy-are driving the bronchiectasis drugs market into a new era of targeted, patient-focused respiratory care.

SCOPE OF STUDY:

The report analyzes the Bronchiectasis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibiotics, Expectorants, Other Products); Distribution Channel (Online Distribution Channel, Offline Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Akorn Operating Co. LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline plc (GSK)
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Insmed Incorporated
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bronchiectasis Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Chronic Respiratory Conditions Throws the Spotlight on Bronchiectasis as an Under-Treated Disease
    • Growing Clinical Recognition and Diagnostic Rates Spur Demand for Targeted Bronchiectasis Therapies
    • Here's How Advances in High-Resolution Imaging Are Driving Earlier Diagnosis and Therapeutic Intervention
    • Expansion of the Elderly and Immunocompromised Population Strengthens the Business Case for Long-Term Drug Management
    • Increased Focus on Airway Inflammation and Mucociliary Dysfunction Supports Innovation in Anti-Inflammatory and Mucoactive Drugs
    • Here's the Story: How CF and Non-CF Bronchiectasis Subtypes Are Guiding Precision Drug Development Strategies
    • Rising Use of Real-World Evidence and Biomarker-Based Segmentation Enhances Drug Targeting and Patient Selection
    • Development of Combination Therapies with Bronchodilators and Corticosteroids Drives Portfolio Diversification
    • Global Expansion of Pulmonary Drug Delivery Platforms Supports Innovation in Inhalation-Based Treatment Options
    • Unmet Need for Disease-Modifying Therapies Presents Opportunities for Biologics and Novel Mechanism Agents
    • Increasing Focus on Patient Quality of Life and Symptom Burden Reinforces Market Demand for Long-Term Maintenance Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bronchiectasis Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Expectorants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Expectorants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • JAPAN
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CHINA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • EUROPE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • FRANCE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • GERMANY
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED KINGDOM
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AUSTRALIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • INDIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • LATIN AMERICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MIDDLE EAST
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AFRICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030

IV. COMPETITION